top of page
FBRN20H0007_Epcam CD83_c1-2_edited.jpg


By Predicting Tumor Response With Biosignatures 

Cancer treatment faces a significant gap in the predictability of tumor response, as seen by low real world response rate to first line immunotherapy treatment choices. Root causes of the predictability gap include absence of multimodal data representing comprehensive response readouts such as cell type modulation, genomic, proteomic and spatiomic changes, and the absence of cohort heterogeneity precluding creation of more robust generalizable predictive models


With our experience of processing nearly 24,000 live human tumors over a decade, we can help our clients expand their existing test offerings that today are largely based on genomic readouts only. Tests developed with more horizontal signals in terms of multi-cell type (tumor, stromal, immue) and tumor types, as well as vertical signals in terms of multi-data types (not just genomic) and population types, can achieve superior personalized treatment choices by more precisely matching each patient with available therapies


The Farcast platform has a proven ability to collect multiple response signals for a variety of therapy options across a range of cancers. These signals are the inputs for proprietary Artificial Intelligence (AI) algorithms in the platform that multiplex the data to generate biosignatures for predicting best tumor response from a range of mono or combination therapy choices

Specialty Testing Labs

Augment existing test offerings with TruSign data to personalize treatment choices for cancer patients

Insurers and Payers

Optimize care by preventing wasteful expense on treatments that are unlikely to benefit patients

Cancer Care Centers

Create better patient outcomes and experiences based on each patient’s personal treatment truth

Anchor 1
bottom of page